NICE gives green light to Endomag's magnetic tracer

By staff writers

October 7, 2022 -- The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended Endomag's magnetic lymphatic tracer Magtrace for use in sentinel lymph node biopsy procedures.

Magtrace is injected into the breast and enters the lymphatic system, following the route that potential cancer cells would take if migrating from a breast tumor up into the sentinel lymph nodes, according to Endomag. The tracer then sits in those nodes for up to 30 days and provides a signal for the lymph nodes to be identified, removed, and analyzed to indicate the presence of invasive cancer.

While many U.K. hospitals have already been using Magtrace for years, NICE recommendations are extremely influential in demonstrating to NHS hospitals that a technology can offer improved performance and cost savings, Endomag representatives said.

Endomag awarded CE Mark for breast cancer marker
U.K. cancer care technology developer Endomag has received CE Mark approval for its minimally invasive breast marker Magseed, used to guide surgeons during...
Endomag opens Cambridge headquarters
U.K. cancer care technology developer Endomag has opened new headquarters in Cambridge, U.K.
Endomag begins trial of breast cancer staging system
U.K. cancer care technology developer Endomag said that a pivotal clinical trial is underway in the U.S. for its Sentimag and Sienna+ magnetic detection...

Copyright © 2022

Last Updated pw 10/7/2022 12:21:54 AM